Help | RSS Feed



Caladrius Biosciences, Inc. (NASD:CLBS) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Caladrius Biosciences, Inc. (NASD:CLBS) seasonal charts above shows that a Buy Date of May 14 and a Sell Date of September 12 has resulted in a geometric average return of 16.74% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 45.3% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company’s product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).

To download CLBS seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z